文献速递前列腺癌

18F-Fluciclovine PET/CT 在前列腺癌生化复发中的系统评价

18F-Fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-05-19

该系统评价检索了 MEDLINE、ScienceDirect 和 Cochrane 图书馆,纳入 9 篇文献共 850 例复发性前列腺癌患者,评估 18F-Fluciclovine PET/CT 的检出率。患者层面检出率在 26% 至 83% 之间,78% 的研究检出率超过 50%,检出率与 PSA 水平成比例,即使 PSA < 0.5 ng/mL 也有高达 53% 的检出率。该检查可影响患者管理,两项研究报告 59%–63% 的患者扫描后管理发生改变。

要点

  • 患者层面检出率 26%–83%,78% 的研究检出率 > 50%。
  • 检出率与 PSA 成比例,PSA < 0.5 ng/mL 时检出率可达 53%。
  • 两项研究报告 59%–63% 的患者扫描后管理发生改变。

核心结论

  • 18F-Fluciclovine PET/CT 在复发性前列腺癌中表现出良好的诊断性能,并带来可测量的临床获益。
  • 严格遵循推荐的显像方案可能有助于优化检出率。

研究设计与样本

  • 系统文献综述,检索 MEDLINE、ScienceDirect 和 Cochrane 图书馆,检索时间为 2020 年 10 月,采用 PRISMA 标准,不限制发表时间。
  • 纳入报告 ≥25 例复发性前列腺癌患者层面 18F-Fluciclovine 检出率的前瞻性研究。
  • 共检索到 321 篇独特文献,最终纳入 9 篇(6 篇论文和 3 篇会议摘要),合计 850 例患者。

主要发现

  • 多数研究(n=6)依据 ASTRO-Phoenix 标准、EAU-ESTRO-SIOG 和/或 ASTRO-AUA 指南定义生化复发。
  • 患者 PSA 水平范围为 0.02–301.7 ng/mL,各研究的中位水平为 0.34–4.10 ng/mL(n=8)。
  • 约 64% 的患者接受过前列腺切除术,但三项研究仅关注前列腺切除术后患者。
  • 患者层面总检出率在各研究间为 26%–83%,78% 的研究报告检出率 > 50%。
  • 检出率与 PSA 成比例,但即使在 PSA < 0.5 ng/mL 时也有高达 53% 的检出率报告。

临床怎么用

  • 18F-Fluciclovine PET/CT 可用于前列腺癌生化复发患者的再分期,检出率与 PSA 水平相关。
  • 该检查结果可影响患者管理决策,并可能改善放疗计划引导下的生存结局。
  • 遵循推荐的显像方案可能有助于优化检出率。

局限性

  • 对显像方案指南的依从性异质,给药活度、摄取时间和扫描时间存在差异。
  • 纳入研究数量有限(9 篇),其中包含 3 篇会议摘要。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A systematic literature review of the performance of 18Fluorine-fluciclovine PET/CT for imaging of men with recurrent prostate cancer was performed. METHODS: Scientific literature databases (MEDLINE, ScienceDirect and Cochrane Libraries) were searched systematically during Oct 2020 using PRISMA criteria. No limit was put on the date of publication. Prospective studies reporting a patient-level 18F-fluciclovine detection rate (DR) from ≥25 patients with recurrent prostate cancer were sought. Proceedings of relevant meetings held from 2018 through Oct 2020 were searched for abstracts meeting criteria. RESULTS: Searches identified 321 unique articles. In total, nine articles (six papers and three conference abstracts), comprising a total of 850 patients met inclusion criteria. Most studies (n = 6) relied on ASTRO-Phoenix Criteria, EAU-ESTRO-SIOG, and/or ASTRO-AUA guidelines to identify patients with biochemical recurrence. Patients' PSA levels ranged from 0.02-301.7 ng/mL (median level per study, 0.34-4.10 ng/mL [n = 8]). Approximately 64% of patients had undergone prostatectomy, but three studies focused solely on post-prostatectomy patients. Adherence to imaging protocol guidelines was heterogeneous, with variance seen in administered activity, uptake and scan times. Overall patient-level DR varied between studies from 26% to 83%, with 78% of studies reporting a DR > 50%. DR was proportional to PSA, but even at PSA < 0.5 ng/mL DR of up to 53% were reported. Prostate/bed DR (n = 7) ranged from 18% to 78% and extra-prostatic rates (n = 6) from 8% to 72%. Pelvic node and bone lesion DR ranged from 8% to 47% and 0% to 26%, respectively (n = 5). 18F-Fluciclovine PET/CT was shown to impact patient management and outcomes. Two studies reported 59-63% of patients to have a management change post-scan. A further study showed significant increase in failure-free survival following 18F-fluciclovine-guided compared with conventional imaging-guided radiotherapy planning. CONCLUSIONS: 18F-Fluciclovine PET/CT shows good performance in patients with recurrent prostate cancer leading to measurable clinical benefits. Careful adherence to recommended imaging protocols may help optimize DR.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Rais-Bahrami S, Efstathiou JA, Turnbull CM, et al. 18F-Fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review. Prostate Cancer Prostatic Dis. 2021. PMID: 34012062. doi:10.1038/s41391-021-00382-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。